To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

Exclusion Criteria

• •Patients with other diagnoses leading to diarrhea, including colorectal neoplasia, ulcerative colitis, Crohn's disease, celiac disease, chronic pancreatitis, drug-induced diarrhea or active infection AND Patients who have not been investigated by standard clinical assessments to exclude these disorders.
• •Treatment with bile acid sequestrants (colestyramine, colestipol, colesevelam) for 2 weeks before the first dose of LJN452. A washout of 14 days for these agents will be allowed before first dosing.
• •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
• •A positive Hepatitis B surface antigen or Hepatitis C test result.
• •History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.